Events

Apollo Therapeutics is pleased to share that Rachel Gurrell PhD, VP, Global Program Lead and Matthew Cardinal, Senior Clinical Scientist will be presenting at the AASLD Liver Meeting taking place 7 – 11 November in Washington DC.

The team will present a poster of distinction on APL-18881, a novel FGF21 and GLP-1 bispecific fusion protein that was evaluated in a Phase 1b trial in adults with poorly controlled diabetes. The data demonstrated:

– Dose-dependent improvement in metabolic and liver health-related endpoints
– Clinically meaningful and statistically significant reduction in liver fat fraction

Many thanks to our co-authors including Rohit Loomba.

This data supporting further clinical development of APL-18881 in cardiometabolic and liver diseases will be presented on Monday November 10, 13.00 – 14.00pm EDT.